MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma
| Autor: | Bernard Klein, J. Coste, E. Legouffe, T. Rousset, Thierry Rème, C. Segara, Ren-Xiao Sun, M. Fabbro, Jean-François Rossi |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Tumor suppressor gene DNA Mutational Analysis Chromosomal translocation Gene mutation Polymerase Chain Reaction Translocation Genetic Gene product Antineoplastic Combined Chemotherapy Protocols Tumor Cells Cultured medicine Humans ATP Binding Cassette Transporter Subfamily B Member 1 Aged P-glycoprotein Aged 80 and over Chromosomes Human Pair 14 biology Lymphoma Non-Hodgkin DNA Neoplasm Hematology Gene rearrangement Middle Aged Genes p53 Prognosis medicine.disease Drug Resistance Multiple Genes bcl-2 Neoplasm Proteins Lymphoma Gene Expression Regulation Neoplastic Multiple drug resistance Treatment Outcome Proto-Oncogene Proteins c-bcl-2 Drug Resistance Neoplasm Disease Progression biology.protein Cancer research Female Chromosomes Human Pair 18 |
| Zdroj: | Clinical & Laboratory Haematology. 20:87-94 |
| ISSN: | 0141-9854 |
| DOI: | 10.1046/j.1365-2257.1998.00090.x |
| Popis: | Non-Hodgkin's lymphomas (NHL) are B-cell malignancies which generally present molecular abnormalities, such as bcl-2 translocation t(14; 18) predominantly in the follicular subgroup. Other molecular events have been described in NHL, including p53 gene mutation and overexpression of one chemoresistance mechanism, the multidrug resistance system, P-glycoprotein (MDR 1/P-gp). In this study, we analysed samples from 44 NHL patients with the presence of the bcl-2 major breakpoint region (MBR) rearrangement in 29 and without in 15. Immunochemical analysis revealed that 39 samples were positive for bcl-2 protein expression in tumoral cells (88.6%). Seventeen (38.6%) patients expressed P-gp and 9 (20.5%) expressed p53 proteins. Eleven patients expressed both bcl-2 and P-gp proteins, four expressed bcl-2 and p53 proteins whereas four expressed bcl-2, p53 and P-gp proteins. Our results confirm the importance of p53 expression as a key prognostic factor, and no objective response (OR) was found in patients with p53 positivity. MBR rearrangement was not associated with poor response to chemotherapy (62.1% OR in MBR positive patients v. 60% OR in MBR negative patients). The clinical impact of P-gp cannot be identified because no relationship was observed between P-gp expression and prognosis (58.8% OR in P-gp positive patients v. 63% OR in P-gp negative patients). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|